Reye syndrome labeling
This article was originally published in The Tan Sheet
Executive Summary
"OTC feedback" meeting scheduled between FDA and the Aspirin Foundation of America on April 5 to address the labeling of all oral and rectal aspirin products and non-aspirin salicylates. In recent comments to the agency, AFA opposed an FDA proposal to require a Reye syndrome warning on all aspirin and non-aspirin salicylates ("The Tan Sheet" Jan. 10, p. 3)